Prostar PMA approval supported by independent Harvard analysis, Perclose says.
This article was originally published in The Gray Sheet
PERCLOSE PROSTAR PMA APPROVAL SUPPORTED BY HARVARD DATA CENTER ANALYSIS, the firm says in an Aug. 28 press release. The one-paragraph statement responds to competitor Datascope's Aug. 6 citizen's petition to FDA seeking revocation of a premarket approval application for the suture-based system for arterial access site closure. Perclose says it does not plan to submit a detailed response to the Datascope petition because it believes its PMA stands on its own merits.
You may also be interested in...
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.